08/04/2021 4:40 PM
Clarín.com
Politics
Updated 08/04/2021 4:53 PM
The Government announced on Wednesday the first results
of the vaccine interchangeability study
, which will allow the combination of productions from different origins to advance inoculation due to concerns about the delta variant of the coronavirus.
"It is an important step in the strategic plan" for vaccination, Minister Carla Vizzotti said.
"Argentina is working to carry out these studies that are also important for the region, since we use the same vaccines," he added.
The combination gives "many possibilities of analogous and heterologous schemes," said the minister.
And he recalled that in the study "Modern was incorporated a few days ago."
Vizzotti said that the work "has the backing of specialists and experts" and that the first "results were satisfactory."
In this way, the vaccine combination plan will begin in the next few hours with the production of Moderna.
"We have the doses of Sputnik that Richmond will do throughout this month. And the
million and a half of Moderna
, which will begin to be distributed so
that starting tomorrow,
launch the strategic plan and begin the acceleration of second-dose vaccines," he clarified. Vizzotti.
The 3.5 million doses of Moderna, which arrived in Argentina as a donation from the United States, were initially used to vaccinate adolescents with comorbidities.
Then continued with the general population of boys between 12 and 17 years old was evaluated.
However, as the minister announced on Tuesday and as confirmed this Wednesday, the
remaining 1.7 million doses
of Moderna will be made available to complete already open schemes.
In that sense, he said that the target in the vaccine combination campaign will be those
over 50 with comorbidities
.
Furthermore, "those with the longest waiting time for the second dose" will be privileged.
Both Nicolás Kreplak, Buenos Aires minister, and Fernán Quirós, Buenos Aires minister, announced that
this Thursday morning they will give information
on how the possibility of choosing the homologous or heterologous scheme will be.
In addition, Quirós clarified that there is still no conclusive information on the advisability of using the Sinopharm vaccine in interchangeability.
Meeting at La Rosada
The announcement came after a meeting between Carla Vizzotti, Santiago Cafiero and the City and Province Health Ministers, Nicolás Kreplak and Fernán Quirós.
The first results of the coronavirus vaccine combination study, which is also being carried out in three other provinces, were discussed there.
The interchangeability of Sputnik V with AstraZeneca, Sinopharm and Moderna was analyzed.
"Everything indicates that the combination of vaccines is possible. In other countries it is being done and in general a good response is expected in terms of safety and also in terms of efficacy," said the Minister of Science, Technology and Innovation, Roberto Salvarezza, before the meeting at Casa Rosada.
On Tuesday Minister Vizzotti had already shown hope.
The official recalled other international studies and assured that there are indications that interchangeability may even be
more immunogenic
(create more defenses) than the regular scheme.
Carla Vizzotti greets Fernán Quirós at the door of the Casa Rosada.
Photo German Garcia Adrasti
"The theory is supported that the interchangeability of vaccines may be even more immunogenic, further stimulating the immune system to generate antibodies and defenses," Vizzotti said Tuesday at
C5N
.
The combination of vaccines is one of the responses to the
lack of second doses of Sputnik V
, just as concern about the
Delta variant
grows
.
In this context, Russia assured this Wednesday that this month it will "completely resolve" the delivery of second doses of Sputnik V.
Given the delay in the arrival of vaccines, the authorities explored the possibility of combining different productions.
In the preview of the announcement, it had been anticipated that the one that would have the best performance is that of AstraZeneca, which shares technology with the Russian one (they are non-replicative viral vectors).
For its part, Sinopharm works with inactivated virus and those of Pfizer and Moderna do so with a messenger RNA platform.
In addition, the Gamaleya Institute approved the local production of the second Sputnik element, so that in August
3 million doses
of this product would be produced at the Richmond laboratory facilities, in Greater Buenos Aires.
News in development.
DS
Look also
Russia assures that this month it will "completely resolve" the delivery of second doses of Sputnik V
WHO asks rich countries to postpone the third doses to be able to vaccinate the poorest
